Literature DB >> 29950359

Severe, reversible dysphagia and malnutrition in a patient with tumour-induced hypophosphataemia.

Tone Ramsli1, Jørgen Valeur2, Mikkel Pretorius3, Per Gerlyng1.   

Abstract

Up to 20% of hospitalised patients may have low serum phosphate concentrations. In certain groups, such as patients with chronic alcohol overconsumption, severe trauma or sepsis, the prevalence may be 30%-50%. Profound hypophosphataemia is less common, but may lead to severe physiological disturbances. In rare cases, hypophosphataemia is caused by phosphaturic substances excreted from a tumour. Osteomalacia with chronic bone pain and fractures, as well as muscle weakness, is common in such patients. The tumours are often small and difficult to detect. Studies suggest that fibroblast growth factor 23 is a reliable marker for detection of these tumours. Persistent hypophosphatemia unresponsive to supplements should raise clinical alertness. With complete resection of the neoplasm, the symptoms rapidly reverse. If the tumour cannot be removed, treatment relies on supplementation with phosphate and active vitamin D compounds. We present a case report of a patient with severe hypophosphataemia, osteomalacia, dysphagia and malnutrition. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  calcium and bone; endocrinology; gastroenterology; malnutrition; renal medicine

Mesh:

Year:  2018        PMID: 29950359      PMCID: PMC6020900          DOI: 10.1136/bcr-2017-223873

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Oncogenic osteomalacia--a complex dance of factors.

Authors:  Thomas O Carpenter
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

2.  Association of hypophosphatemia with failure-to-wean from mechanical ventilation.

Authors:  Mohammad H Alsumrain; Sami Abdul Jawad; Nashat B Imran; Sandeep Riar; Vincent A DeBari; Marc Adelman
Journal:  Ann Clin Lab Sci       Date:  2010       Impact factor: 1.256

3.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

Review 4.  Tumor-Induced Osteomalacia: an Up-to-Date Review.

Authors:  Anke H Hautmann; Matthias G Hautmann; Oliver Kölbl; Wolfgang Herr; Martin Fleck
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

5.  Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia.

Authors:  Yasuo Imanishi; Jun Hashimoto; Wataru Ando; Keisuke Kobayashi; Takafumi Ueda; Yuki Nagata; Akimitsu Miyauchi; Hajime M Koyano; Hiroshi Kaji; Takatoshi Saito; Koichi Oba; Yasato Komatsu; Tomoaki Morioka; Katsuhito Mori; Takami Miki; Masaaki Inaba
Journal:  J Bone Miner Metab       Date:  2011-07-08       Impact factor: 2.626

6.  Approach to the hypophosphatemic patient.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2012-03       Impact factor: 5.958

Review 7.  Hypophosphatemia: an update on its etiology and treatment.

Authors:  André Gaasbeek; A Edo Meinders
Journal:  Am J Med       Date:  2005-10       Impact factor: 4.965

8.  Oncogenic Osteomalacia: An Approach to Diagnosis with a Case Report.

Authors:  Biswajit Dey; Debasis Gochhait; Hema Subramanian; Madhusudhanan Ponnusamy
Journal:  J Clin Diagn Res       Date:  2017-04-01

9.  Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).

Authors:  Michelle Houang; Adele Clarkson; Loretta Sioson; Marianne S Elston; Roderick J Clifton-Bligh; Michael Dray; Dominique Ranchere-Vince; Anne-Valerie Decouvelaere; Arnaud de la Fouchardiere; Anthony J Gill
Journal:  Hum Pathol       Date:  2013-09-20       Impact factor: 3.466

Review 10.  Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.

Authors:  Jason Stubbs; Shiguang Liu; L Darryl Quarles
Journal:  Semin Dial       Date:  2007 Jul-Aug       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.